Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults.
Abdominal adiposity
Cause-specific mortality
Gluteo-femoral adiposity
Mexico
Prospective cohort study
Journal
European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430
Informations de publication
Date de publication:
05 05 2022
05 05 2022
Historique:
received:
01
12
2020
revised:
30
01
2021
accepted:
18
02
2021
pubmed:
12
3
2021
medline:
10
5
2022
entrez:
11
3
2021
Statut:
ppublish
Résumé
Results of previous studies of abdominal adiposity and risk of vascular-metabolic mortality in Hispanic populations have been conflicting. We report results from a large prospective study of Mexican adults with high levels of abdominal adiposity. A total of 159 755 adults aged ≥35 years from Mexico City were enrolled in a prospective study and followed for 16 years. Cox regression, adjusted for confounders, yielded mortality rate ratios (RRs) associated with three markers of abdominal adiposity (waist circumference, waist-hip ratio, and waist-height ratio) and one marker of gluteo-femoral adiposity (hip circumference) for cause-specific mortality before age 75 years. To reduce reverse causality, deaths in the first 5 years of follow-up and participants with diabetes or other prior chronic disease were excluded. Among 113 163 participants without prior disease and aged 35-74 years at recruitment, all adiposity markers were positively associated with vascular-metabolic mortality. Comparing the top versus bottom tenth of the sex-specific distributions, the vascular-metabolic mortality RRs at ages 40-74 years were 2.32 [95% confidence interval (CI) 1.84-2.94] for waist circumference, 2.22 (1.71-2.88) for the waist-hip ratio, 2.63 (2.06-3.36) for the waist-height ratio, and 1.58 (1.29-1.93) for hip circumference. The RRs corresponding to each standard deviation (SD) higher usual levels of these adiposity markers were 1.34 (95% CI 1.27-1.41), 1.31 (1.23-1.39), 1.38 (1.31-1.45), and 1.18 (1.13-1.24), respectively. For the markers of abdominal adiposity, the RRs did not change much after further adjustment for other adiposity markers, but for hip circumference the association was reversed; given body mass index and waist circumference, the RR for vascular-metabolic mortality for each one SD higher usual hip circumference was 0.80 (0.75-0.86). In this study of Mexican adults, abdominal adiposity (and in particular the waist-height ratio) was strongly and positively associated with vascular-metabolic mortality. For a given amount of general and abdominal adiposity, however, higher hip circumference was associated with lower vascular-metabolic mortality.
Identifiants
pubmed: 33693634
pii: 6163117
doi: 10.1093/eurjpc/zwab038
pmc: PMC9071366
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
730-738Subventions
Organisme : Medical Research Council
ID : MR/R007764/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00017/2
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/13/1/30181
Pays : United Kingdom
Organisme : Breast Cancer Now
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Clin Chem. 2002 Sep;48(9):1627-9
pubmed: 12194959
Nat Rev Dis Primers. 2017 Jun 15;3:17034
pubmed: 28617414
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Atherosclerosis. 2006 Dec;189(2):420-7
pubmed: 16442545
Diabetes Care. 2016 Nov;39(11):1996-2003
pubmed: 27733421
Nat Rev Endocrinol. 2015 Feb;11(2):90-100
pubmed: 25365922
Stat Med. 2004 Jan 15;23(1):93-104
pubmed: 14695642
PLoS One. 2020 Nov 5;15(11):e0241841
pubmed: 33152746
N Engl J Med. 2016 Nov 17;375(20):1961-1971
pubmed: 27959614
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Obesity (Silver Spring). 2018 Aug;26(8):1372-1380
pubmed: 30070038
J Gerontol A Biol Sci Med Sci. 2015 Apr;70(4):503-10
pubmed: 25209254
Lancet. 1990 Mar 31;335(8692):765-74
pubmed: 1969518
Ann Intern Med. 2019 Sep 17;171(6):397-405
pubmed: 31404923
N Engl J Med. 2016 Jun 23;374(25):2430-40
pubmed: 27074389
N Engl J Med. 2008 Nov 13;359(20):2105-20
pubmed: 19005195
Int J Epidemiol. 2006 Apr;35(2):243-9
pubmed: 16556648
PLoS Genet. 2019 Oct 24;15(10):e1008405
pubmed: 31647808
Eur J Clin Nutr. 2013 Jun;67(6):573-85
pubmed: 23511854
Lancet. 2005 Nov 5;366(9497):1640-9
pubmed: 16271645
Lancet. 2011 Mar 26;377(9771):1085-95
pubmed: 21397319
Hypertension. 2017 Apr;69(4):608-614
pubmed: 28223471
Lancet Glob Health. 2019 Oct;7(10):e1332-e1345
pubmed: 31488387